Alzamend Neuro ALZN
NASDAQ ALZN
$1.67 -0.04 (-2.34%)
As of: Sep 10, 2026 · 12:03 PM EDT

Alzamend Neuro (ALZN) Convertible Debt (2021)

Alzamend Neuro's (ALZN) quarterly Convertible Debt came in at $344893.0 in Q4 2021, up 1.41% quarter-over-quarter from $340098.0 in Q3 2021.

Analysis

Alzamend Neuro (ALZN) Convertible Debt (2021) Analysis & Trends

Alzamend Neuro has disclosed Convertible Debt across 1 years of filings, most recently posting $344893.0 for Q4 2021.

  • In Q4 2021, Convertible Debt changed N/A year-over-year to $344893.0; the TTM figure through Oct 2021 stood at $344893.0 (changed N/A YoY), while the FY2021 annual figure was $335303.0, changed N/A from the prior year.
  • Convertible Debt came in at $344893.0 for Q4 2021 at Alzamend Neuro, up from $340098.0 in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $344893.0 in Q4 2021 to a low of $335303.0 in Q2 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.51 Bn 192.52 Bn 7.24 Bn
2 Gilead Sciences 179.28 Bn 176.11 Bn 6.22 Bn
3 Vertex Pharmaceuticals 131.06 Bn 123.21 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.61 Bn 73.62 Bn 3.93 Bn
5 Argenx Se 60.71 Bn 55.52 Bn 1.37 Bn
6 Moderna 53.60 Bn 48.46 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.41 Bn 30.10 Bn 992.69 Mn
8 Biogen 31.79 Bn 30.50 Bn 1.96 Bn
9 Roivant Sciences 29.11 Bn 29.11 Bn 1.16 Mn
10 Alzamend Neuro 5.57 Mn 5.57 Mn -
Historic Data

Historic Data

Download Data
DateValue
Oct 31, 2021 344,893.00
Jul 31, 2021 340,098.00
Apr 30, 2021 335,303.00